BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 762421)

  • 1. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
    Sobel AT; Cooper NR; Schreiber RD
    J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
    Daha MR; van Es LA
    J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
    Baker PJ; Adler S; Yang Y; Couser WG
    J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistently circulating C3 nephritic factor (C3 NeF)-stabilized alternative pathway C3 convertase (C3 CoF) in serum of an 11-year-old girl with meningococcal septicemia--simultaneous occurrence with free C3 NeF.
    Wahn V; Müller W; Rieger C; Rother U
    Pediatr Res; 1987 Aug; 22(2):123-9. PubMed ID: 3658535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
    Strunk RC; Giclas PC
    J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
    [No Abstract]   [Full Text] [Related]  

  • 12. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
    Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
    J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
    Daha MR; van Es LA
    J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
    Isenman DE; Podack ER; Cooper NR
    J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of activation of the classical pathway of complement by monoclonal IgE (DES). Restricted regulation of C4b by C4b-binding protein.
    Saint-Remy JM
    Eur J Immunol; 1984 Mar; 14(3):254-9. PubMed ID: 6608450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies of complement, nephritic factor, and circulating immune complexes in chronic mesangiocapillary glomerulonephritis types I and II (author's transl)].
    Mirapeix E; Yagüe J; Vives J; Revert L
    Med Clin (Barc); 1981 Jun; 77(1):21-6. PubMed ID: 7253758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.
    Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD
    Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.